Spots Global Cancer Trial Database for alk gene mutation
Every month we try and update this database with for alk gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | NCT05534854 | Renal Tumor His... Kidney Cancer Renal Cell Carc... Familial Renal ... HLRCC VHL Syndrome BAP1 Tumor Pred... FLCN Gene Mutat... ALK Gene Mutati... FH Gene Mutatio... Birt-Hogg-Dube ... MET Gene Mutati... Cutaneous Leiom... Cutaneous Leiom... | Gene test | 2 Years - | RenJi Hospital | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib | NCT06378892 | Non Small Cell ... ALK Gene Mutati... | Lorlatinib | 18 Years - | Centro di Riferimento Oncologico - Aviano | |
| Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) | NCT05724004 | Radiotherapy Si... Non-small Cell ... ALK Gene Mutati... | SBRT/SRS/radiat... | 20 Years - | Karolinska University Hospital | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| Alectinib Pharmacokinetic in Patients With NSCLC | NCT05713006 | Non-small Cell ... ALK Gene Mutati... | Alectinib Oral ... | 18 Years - | Instituto Nacional de Cancerologia de Mexico | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | NCT03868423 | Advanced Malign... ALK Fusion Prot... ALK Gene Amplif... ALK Gene Mutati... Locally Advance... Metastatic Mali... Metastatic Mali... Metastatic Mali... ROS1 Fusion Pos... ROS1 Gene Ampli... ROS1 Gene Mutat... | Brigatinib Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients | NCT04708639 | Lung Cancer ALK Gene Mutati... Resistance, Dis... Mutation | Alectinib | 18 Years - | Aarhus University Hospital | |
| Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy | NCT03042221 | Non-Small Cell ... Non-Small Cell ... EGFR Gene Mutat... ALK Gene Mutati... ROSE Cluster 1 BRAF V600E | 18 Years - 85 Years | University of Colorado, Denver | ||
| Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) | NCT06234579 | ALK Gene Mutati... NSCLC Stage IV ALK Sensitizing... | Biopsy (tissue ... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) | NCT05724004 | Radiotherapy Si... Non-small Cell ... ALK Gene Mutati... | SBRT/SRS/radiat... | 20 Years - | Karolinska University Hospital | |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | NCT05200481 | Non Small Cell ... ALK Gene Mutati... | Brigatinib 180 ... Carboplatin Pemetrexed | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes | NCT05534854 | Renal Tumor His... Kidney Cancer Renal Cell Carc... Familial Renal ... HLRCC VHL Syndrome BAP1 Tumor Pred... FLCN Gene Mutat... ALK Gene Mutati... FH Gene Mutatio... Birt-Hogg-Dube ... MET Gene Mutati... Cutaneous Leiom... Cutaneous Leiom... | Gene test | 2 Years - | RenJi Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
